Decreased Antithrombin III Activity in Diabetes May Be Due to Non-Enzymatic Glycosylation – A Preliminary Report

Summary

Antithrombin III activity was moderately but significantly decreased in insulin dependent diabetics (p <0.005), while no difference has been found between the diabetic (n = 25) and control groups (n = 22) in antithrombin III plasma concentration.

Moreover, antithrombin III activity was inversely correlated with glycosylated plasma proteins (r = -0.57; p <0.01).

These data show that in diabetes there is a depressed biological activity of antithrombin III and suggest that this reflects nonenzymatic glycosylation of antithrombin III protein.

Keywords

Antithrombin III - Diabetes - Non-enzymatic glycosylation

• References

• 1 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactors. J Biol Chem 1973; 248: 6490-6498
• 2 Banerjee RN, Sahni AL, Kumar V, Arya M. Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis. Thrombos Diathes Haemorrh 1974; 31: 339-345
• 3 Fuller JH, Keen H, Jarrett RJ. Hemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966
• 4 Zucker ML, Gomperts EP, Russel D, Joffe B, Feesey M, Kuschke R, Seftel H. Antithrombin functional activity after saturated and unsaturated fatty meals and fasting in normal subjects and some disease states. Thromb Res 1979; 15: 37-46
• 5 Sowers JR, Tuck ML, Sowers DK. Plasma antithrombin III and thrombin generation time: correlation with hemoglobin A₁ and fasting serum glucose in young diabetic women. Diabetes Care 1980; 3: 655-658
• 6 Bunn HF. Non enzymatic glycosylation of protein-relevance to diabetes. Am J Med 1981; 70: 325-330
• 7 Kennedy AL, Merimee TS. Glycosylated serum protein and hemoglobin A_1c levels to measure control of glycemia. Ann Intern Med 1981; 95: 56-58
• 8 Abildgaard U, Lie M, Odegård OR. Antithrombin (heparin-cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-554
• 9 Yue DK, Morris K, Mc Lennan S, Turtle JR. Glycosylation of plasma protein and its relation to glycosylated hemoglobin in diabetes. Diabetes 1980; 29: 296-300
• 10 Hedner U, Nilsson IM. Antithrombin III in a clinical material. Thromb Res 1973; 3: 631-645
• 11 Jones RL, Peterson CM. The fluid phase of coagulation and the accelerated atherosclerosis of diabetes mellitus. Diabetes 1981; 30 suppl (Suppl. 02) 33-38
• 12 Gandolfo GM, De Angelis A, Torresi MV. Determination of antithrombin III activity by different methods in diabetic patients. Haemostasis 1980; 9: 15-19
• 13 Ceriello A, Dello Russo PP, Sgambato S, Giugliano D. Glycosylated hemoglobin and reticulocyte counts in diabetes. Diabetologia 1982; 22: 223
• 14 Ceriello A, Giugliano D, Dello Russo PP, Passariello N. Hypomagnesemia in relation to diabetic retinopathy. Diabetes Care 1982; 5: 558-559
• 15 Ceriello A, Giugliano D, Dello Russo PP, Passariello N, Saccomanno F, Sgambato S. Glycosaminoglycans in human diabetes. Diab Metab 1983; 9: 32-34
• 16 Ditzel J. Increased haemoglobin A_1c and 2, 3 diphosphoglycerate in diabetes, and their effects on red-cell oxigen-releasing capacity. Lancet 1973; 2: 1034
• 17 Dolhofer R, Wieland OH. Preparation and biological properties of glycosylated insulin. FEBS letters 1979; 100: 133-136
• 18 Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982; 31: 283-291